Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-32. [PMID: 20117285 DOI: 10.1016/j.ijrobp.2009.09.042] [Citation(s) in RCA: 331] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Accepted: 09/24/2009] [Indexed: 02/08/2023]

For:	Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-32. [PMID: 20117285 DOI: 10.1016/j.ijrobp.2009.09.042] [Citation(s) in RCA: 331] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Accepted: 09/24/2009] [Indexed: 02/08/2023]

Number

Cited by Other Article(s)

van Werkhoven LA, Milder MTW, Schillemans W, Hoogeman MS, Nout RA, Nuyttens JJ. Computed Tomography Guided Online Adaptive Stereotactic Body Radiation Therapy for Lymph Node Oligometastases: Impact on Dose to Target and Organs at Risk. Int J Radiat Oncol Biol Phys 2025;122:760-769. [PMID: 40122299 DOI: 10.1016/j.ijrobp.2025.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2024] [Revised: 01/31/2025] [Accepted: 03/08/2025] [Indexed: 03/25/2025]

Abstract

PURPOSE

This study investigates the radiation dose in abdominal and pelvic lymph node oligometastases (A-P LN) and gastrointestinal organs (GIOs) of patients undergoing computed tomography (CT) guided online adaptive stereotactic body radiation therapy in a phase 2 study. The study aimed to increase the dose to the target iso-toxically.

METHODS AND MATERIALS

Patients with oligometastatic A-P LN received 45 Gy in 5 fractions on the CyberKnife. Each patient had 3 plans created using a pretreatment planning CT scan: plan A, standard of care (SOC) plan based on the planning CT; plan B, adaptive plan with GIO contours from a diagnostic CT; plan C, adaptive plan with 45 Gy prescribed to the 80% isodose-line. After a prefraction in-room CT scan, the radiation therapy technologist used a decision tree to select the plan with the highest target coverage without exceeding organs at risk constraints. Dose volume histogram parameters were extracted from the original planning CT, the fraction CT with the selected library plan and the fraction CT with the SOC plan.

RESULTS

In total, 52 patients were included, and 55 online adaptive treatments were performed. An adaptive plan was chosen in 58% of fractions and in 78% of the patients and resulted in a significant higher Dmean compared with the planned dose (100.6 biologically effective dose (BED10) vs 95 BED10; P < .001). The GIO D0.5cc was 2.7 Gy EQD23 higher for the SOC plan on the fraction CT compared with the SOC on the original planning CT (P = .009). There was no significant difference in GIO D0.5cc between the SOC plan on the fraction CT and the selected plan on the fraction CT.

CONCLUSIONS

CT-based online adaptive stereotactic body radiation therapy for A-P LN oligometastases, using a library of plans, led to an adaptive plan selection in the majority of patients. This workflow enabled a mean BED10 5 Gy isotoxic dose escalation to the gross tumor volume.

Collapse

Tanimoto Y, Oita M, Koshi K, Ishiwaki K, Hiramatsu F, Sasaki T, Ise H, Miyagawa T, Maeda T, Okahira S, Hamaguchi T, Kawaguchi T, Funada N, Yamamoto S, Hiroshige A, Mukai Y, Yoshida S, Fujita Y, Nakahira A, Honda H. Standardization of radiation therapy quality control system through mutual quality control based on failure mode and effects analysis. Radiol Phys Technol 2025;18:78-85. [PMID: 39557763 PMCID: PMC11876268 DOI: 10.1007/s12194-024-00857-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Revised: 10/29/2024] [Accepted: 10/30/2024] [Indexed: 11/20/2024]

Affiliation(s)

Yuki Tanimoto Department of Radiology, NHO Kure Medical Center and Chugoku Cancer Center, Kure, 737-0023, Japan Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, 700-8558, Japan
Masataka Oita Faculty of Interdisciplinary Science and Engineering in Health Systems, Department of Healthcare Science, Okayama University, 3-1-1 Tsushima-Naka, Kita-Ku, Okayama, 700-8530, Japan.
Kazunobu Koshi Department of Radiology, NHO Fukuyama Medical Center, Fukuyama, 720-8520, Japan
Kiyoshi Ishiwaki Department of Radiology, NHO Iwakuni Medical Center, Iwakuni, 740-8510, Japan
Futoshi Hiramatsu Department of Radiology, NHO Hamada Medical Center, Hamada, 697-8511, Japan
Toshihisa Sasaki Department of Radiology, NHO Higashi-Hiroshima Medical Center, Higashi-Hiroshima, 739-0041, Japan
Hiroki Ise Department of Radiology, NHO Iwakuni Medical Center, Iwakuni, 740-8510, Japan
Takashi Miyagawa Department of Radiology, NHO Kanmon Medical Center, Shimonoseki, 752-8510, Japan
Takeshi Maeda Department of Radiology, NHO Kochi National Hospital, Kochi, 780-8507, Japan
Shinsuke Okahira Department of Radiology, NHO Yamaguchi-Ube Medical Center, Ube, 755-0241, Japan
Takashi Hamaguchi Department of Radiology, NHO Okayama Medical Center, Okayama, 701-1192, Japan
Tatsuya Kawaguchi Department of Radiology, NHO Shikoku Medical Center for Children and Adults, Zentsuji, 765-8507, Japan
Norihiro Funada Department of Radiology, NHO Hamada Medical Center, Hamada, 697-8511, Japan
Shuhei Yamamoto Department of Radiology, NHO Fukuyama Medical Center, Fukuyama, 720-8520, Japan
Akira Hiroshige Department of Radiology, NHO Shikoku Cancer Center, Matsuyama, 791-0280, Japan
Yuki Mukai Department of Radiology, NHO Shikoku Cancer Center, Matsuyama, 791-0280, Japan
Shohei Yoshida Department of Radiology, NHO Shikoku Cancer Center, Matsuyama, 791-0280, Japan
Yoshiki Fujita Department of Radiology, NHO Shikoku Cancer Center, Matsuyama, 791-0280, Japan
Atsuki Nakahira Department of Radiology, NHO Shikoku Cancer Center, Matsuyama, 791-0280, Japan
Hirofumi Honda Department of Radiological Technology, Ehime University Hospital, Matsuyama, 791-0295, Japan

Collapse

Franzese C, Louie AV, Kotecha R, Zhang Z, Guckenberger M, Kim MS, Tree AC, Slotman BJ, Sahgal A, Scorsetti M. Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines. Pract Radiat Oncol 2025;15:e172-e188. [PMID: 39419281 DOI: 10.1016/j.prro.2024.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 09/24/2024] [Accepted: 09/25/2024] [Indexed: 10/19/2024]

Lam FC, Guru S, AbuReesh D, Hori YS, Chuang C, Liu L, Wang L, Gu X, Szalkowski GA, Wang Z, Wohlers C, Tayag A, Emrich SC, Ustrzynski L, Zygourakis CC, Desai A, Hayden Gephart M, Byun J, Pollom EL, Rahimy E, Soltys S, Park DJ, Chang SD. Use of Carbon Fiber Implants to Improve the Safety and Efficacy of Radiation Therapy for Spine Tumor Patients. Brain Sci 2025;15:199. [PMID: 40002531 PMCID: PMC11852773 DOI: 10.3390/brainsci15020199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2024] [Revised: 01/22/2025] [Accepted: 02/13/2025] [Indexed: 02/27/2025] Open

Affiliation(s)

Fred C. Lam Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Santosh Guru Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Deyaldeen AbuReesh Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Yusuke S. Hori Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Cynthia Chuang Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Lianli Liu Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Lei Wang Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Xuejun Gu Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Gregory A. Szalkowski Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Ziyi Wang Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Christopher Wohlers Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Armine Tayag Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Sara C. Emrich Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Louisa Ustrzynski Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Corinna C. Zygourakis Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Atman Desai Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Melanie Hayden Gephart Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
John Byun Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Erqi Liu Pollom Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Elham Rahimy Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
Scott Soltys Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; (C.C.); (L.L.); (L.W.); (X.G.); (G.A.S.); (Z.W.); (C.W.); (J.B.); (E.L.P.); (E.R.); (S.S.)
David J. Park Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)
Steven D. Chang Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; (F.C.L.); (S.G.); (D.A.); (Y.S.H.); (A.T.); (S.C.E.); (L.U.); (A.D.); (M.H.G.); (D.J.P.)

Collapse

Coles-Black J, Rahman A, Siva S, Ischia J, Perera M, Bolton D, Lawrentschuk N. Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know. Life (Basel) 2024;14:1683. [PMID: 39768390 PMCID: PMC11678295 DOI: 10.3390/life14121683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2024] [Revised: 12/05/2024] [Accepted: 12/10/2024] [Indexed: 01/11/2025] Open

Lin Y, Qureshi MM, Batra S, Truong MT, Mak KS. Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer. Adv Radiat Oncol 2024;9:101625. [PMID: 39524524 PMCID: PMC11550745 DOI: 10.1016/j.adro.2024.101625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Accepted: 08/12/2024] [Indexed: 11/16/2024] Open

Abstract

Purpose

The optimal delivery schedule for stereotactic body radiation therapy (SBRT) in treating stage I non-small cell lung cancer (NSCLC) is unknown. This study used the National Cancer Database to examine daily versus every other day (QOD) SBRT scheduling, including trends over time and association with survival.

Methods and Materials

The National Cancer Database was used to retrospectively identify patients with stage I NSCLC treated with 3-, 4-, or 5-fraction of SBRT between 2004 and 2016. Survival analysis was performed using the Kaplan-Meier method and Cox regression modeling.

Results

Of 15,269 patients, 3927 (25.7%) received SBRT daily, and 11,342 (74.3%) received treatment QOD. The use of QOD treatment increased from 63.2% in 2007 to 78.3% in 2016, and 5-fraction SBRT increased from 3.7% in 2004 to 51.4% in 2016 (both P < .0001). QOD 5-fraction became the most prevalent scheduling from 2012 to 2016 (28.5% in 2012 to 41.6% in 2016). Factors significantly associated with daily SBRT scheduling included number of fractions, race, lower income, lower comorbidities, and treatment at academic/research programs (all P ≤ .01).Median survival for daily SBRT was 37.9 months versus 38.4 months for QOD (P = .4). On multivariable analysis, no difference was found in overall survival between daily versus QOD scheduling (adjusted hazard ratio [aHR], 0.99; 95% confidence interval [CI], 0.94-1.04; P = .55). Five-fraction SBRT was associated with worse survival versus 3 fractions (aHR, 1.09; 95% CI, 1.03-1.15; P = .002). With 3-fraction SBRT, QOD treatment was associated with improved survival versus daily treatment (aHR, 0.91; 95% CI, 0.84-0.98; P = .02). With 5-fraction SBRT, QOD treatment was associated with worse survival versus daily treatment (aHR, 1.11; 95% CI, 1.02-1.22; P = .02).

Conclusions

QOD SBRT schedules were more frequently used to treat stage I NSCLC than daily regimens by a factor of 3:1, and QOD 5-fraction SBRT became the most common dose schedule after 2012. Three-fraction QOD SBRT was associated with improved survival versus daily, whereas 5-fraction QOD SBRT was associated with worse survival versus daily.

Collapse

Azadbakht J, Condos A, Haynor D, Gibbs WN, Jabehdar Maralani P, Sahgal A, Chao ST, Foote MC, Suh J, Chang EL, Guckenberger M, Mossa-Basha M, Lo SS. The Role of CT and MR Imaging in Stereotactic Body Radiotherapy of the Spine: From Patient Selection and Treatment Planning to Post-Treatment Monitoring. Cancers (Basel) 2024;16:3692. [PMID: 39518130 PMCID: PMC11545634 DOI: 10.3390/cancers16213692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Accepted: 10/28/2024] [Indexed: 11/16/2024] Open

García-Acilu P, García Ruiz-Zorrilla J, Hernando O, Prado A, Chen-Zhao X, Montero A, Martí J, Zucca D, Alonso L, De la Casa MA, Sánchez E, Alonso R, Rubio C, Fernández-Letón P. Analysis of intra-fractional positioning correction performed by cone beam computed tomography in SBRT treatments. Phys Med 2024;125:104502. [PMID: 39216313 DOI: 10.1016/j.ejmp.2024.104502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Revised: 07/12/2024] [Accepted: 08/22/2024] [Indexed: 09/04/2024] Open

Affiliation(s)

P García-Acilu Department of Medical Physics, University Hospital Madrid Puerta del Sur., Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
J García Ruiz-Zorrilla Department of Medical Physics, University Hospital Madrid Puerta del Sur., Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
O Hernando Department of Radiation Oncology, University Hospital Madrid Puerta del Sur, Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
A Prado Department of Medical Physics, University Hospital Madrid Sanchinarro. C/de Oña, 10. 28050, Madrid, Spain.
X Chen-Zhao Department of Radiation Oncology, University Hospital Madrid Puerta del Sur, Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
A Montero Department of Radiation Oncology, University Hospital Madrid Sanchinarro, C/de Oña, 10. 28050, Madrid, Spain.
J Martí Department of Medical Physics, University Hospital Madrid Puerta del Sur., Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
D Zucca Department of Medical Physics, University Hospital Madrid Sanchinarro. C/de Oña, 10. 28050, Madrid, Spain.
L Alonso Department of Medical Physics, University Hospital Madrid Sanchinarro. C/de Oña, 10. 28050, Madrid, Spain.
M A De la Casa Department of Medical Physics, University Hospital Madrid Sanchinarro. C/de Oña, 10. 28050, Madrid, Spain.
E Sánchez Department of Radiation Oncology, University Hospital Madrid Puerta del Sur, Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
R Alonso Department of Radiation Oncology, University Hospital Madrid Puerta del Sur, Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain.
C Rubio Department of Radiation Oncology, University Hospital Madrid Puerta del Sur, Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain; Department of Radiation Oncology, University Hospital Madrid Sanchinarro, C/de Oña, 10. 28050, Madrid, Spain.
P Fernández-Letón Department of Medical Physics, University Hospital Madrid Puerta del Sur., Av. Carlos V, 70. 28938, Móstoles, Madrid, Spain; Department of Medical Physics, University Hospital Madrid Sanchinarro. C/de Oña, 10. 28050, Madrid, Spain.

Collapse

Sarria GR, Wiegreffe S, Gkika E. [New Radiation Therapy Concepts in Non-Metastatic Lung Cancer]. Zentralbl Chir 2024;149:S52-S61. [PMID: 39137762 DOI: 10.1055/a-2365-8743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2024]

Liu W, Feng H, Taylor PA, Kang M, Shen J, Saini J, Zhou J, Giap HB, Yu NY, Sio TS, Mohindra P, Chang JY, Bradley JD, Xiao Y, Simone CB, Lin L. NRG Oncology and Particle Therapy Co-Operative Group Patterns of Practice Survey and Consensus Recommendations on Pencil-Beam Scanning Proton Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies. Int J Radiat Oncol Biol Phys 2024;119:1208-1221. [PMID: 38395086 PMCID: PMC11209785 DOI: 10.1016/j.ijrobp.2024.01.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 11/25/2023] [Accepted: 01/28/2024] [Indexed: 02/25/2024]

Saúde-Conde R, El Ghali B, Navez J, Bouchart C, Van Laethem JL. Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better? Cancers (Basel) 2024;16:2423. [PMID: 39001485 PMCID: PMC11240662 DOI: 10.3390/cancers16132423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2024] [Revised: 06/24/2024] [Accepted: 06/24/2024] [Indexed: 07/16/2024] Open

George B, Baydoun A, Bhat S, Bailey L, Arsenault T, Sun Y, Zhang Y, Zheng Y, Vempati P, Podder T, Biswas T. Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer - Results from a Single Institution Study. Clin Lung Cancer 2024;25:e181-e188. [PMID: 38553326 DOI: 10.1016/j.cllc.2024.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 02/11/2024] [Accepted: 02/19/2024] [Indexed: 06/01/2024]

Salim N, Tumanova K, Popodko A, Libson E. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease. JCO Glob Oncol 2024;10:e2300275. [PMID: 38754052 DOI: 10.1200/go.23.00275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 02/05/2024] [Accepted: 03/05/2024] [Indexed: 05/18/2024] Open

Abstract

PURPOSE

Local ablative therapy, such as radiotherapy or surgery, plays a key role in treatment of patients with oligometastatic disease. Stereotactic ablative body radiotherapy (SABR) comes to the fore as a safe and effective treatment for patients with a limited number of metastases, even those located in hard-to-reach body sites. Many researchers have suggested that metastatsis-directed therapy could improve long-term progression-free survival (PFS) and overall survival (OS) in patients with oligometastases.

PATIENTS AND METHODS

This was a retrospective, single-arm, observational study conducted between July 2015 and February 2022. In our institute, 60 patients with controlled primary tumors and one to five metastases were treated with SABR. Prescribed radiation doses ranged from 12 to 60 Gy administered in one to seven fractions. We aimed to determine whether metastatic-directed therapy using SABR for all oligometastases affects OS and PFS and whether the primary tumor or metastatic site influences OS/PFS.

RESULTS

The most common primary malignancy types were prostate (n = 14), colorectal (n = 10), lung (n = 7), and breast cancers (n = 6). The median follow-up was 30 months, ranging from 9 to 79. The 1-, 3-, and 5-year PFS and OS rates were 54.9%, 37.0%, and 37.0% and 98.3%, 84.4%, and 73.8%, respectively, and the median time to first progression was 15 (range, 2-32) months. Twenty-four (40%) patients had no recurrence. In our analysis, primary tumor site was not an independent prognostic factor. The metastatic site may influence on patient outcome in cases of localized bone and liver metastases.

CONCLUSION

In our retrospective analysis, SABR was associated with favorable levels of PFS and OS in patients with oligometastases. The limitations of our study were lacking high-level evidence, and randomized studies to compare SABR and palliative standard of care are mandatory.

Collapse

Chlorogiannis DD, Moussa AM, Zhao K, Alexander ES, Sofocleous CT, Sotirchos VS. Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer. Diagnostics (Basel) 2024;14:772. [PMID: 38611685 PMCID: PMC11011364 DOI: 10.3390/diagnostics14070772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Revised: 03/28/2024] [Accepted: 04/02/2024] [Indexed: 04/14/2024] Open

Kobayashi H, Eriguchi T, Tanaka T, Ogata T, Osaki N, Suzuki H, Kosugi M, Kumabe A, Sato K, Ishida M. An optimal method of hydrogel spacer insertion for stereotactic body radiation therapy of prostate cancer. Jpn J Radiol 2024;42:406-414. [PMID: 37932639 DOI: 10.1007/s11604-023-01506-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 10/17/2023] [Indexed: 11/08/2023]

Bonù ML, Nicosia L, Turkaj A, Pastorello E, Vitali P, Frassine F, Toraci C, Spiazzi L, Lechiara M, Frittoli B, Grazioli L, Ghirardelli P, Costantino G, Barbera F, Borghetti P, Triggiani L, Portolani N, Buglione M, Dionisi F, Giacomelli I, Lancia A, Magrini SM, Tomasini D. High dose proton and photon-based radiation therapy for 213 liver lesions: a multi-institutional dosimetric comparison with a clinical perspective. LA RADIOLOGIA MEDICA 2024;129:497-506. [PMID: 38345714 PMCID: PMC10942931 DOI: 10.1007/s11547-024-01788-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 01/15/2024] [Indexed: 03/16/2024]

Affiliation(s)

Marco Lorenzo Bonù Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy.
Luca Nicosia Department of Radiation Oncology, Ospedale Sacro Cuore Don Calabria, Negrar, Italy
Ana Turkaj Proton Therapy Center, Trento, Italy
Edoardo Pastorello Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Paola Vitali Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Francesco Frassine Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Cristian Toraci Department of Medical Physics, Spedali Civili di Brescia, Brescia, Italy
Luigi Spiazzi Department of Medical Physics, Spedali Civili di Brescia, Brescia, Italy
Marco Lechiara Department of Radiology, Spedali Civili di Brescia, Brescia, Italy
Barbara Frittoli Department of Radiology, Spedali Civili di Brescia, Brescia, Italy
Luigi Grazioli Department of Radiology, Spedali Civili di Brescia, Brescia, Italy
Paolo Ghirardelli Department of Radiation Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy
Gianluca Costantino Department of Radiation Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy
Fernando Barbera Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Paolo Borghetti Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Luca Triggiani Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Nazario Portolani Department of Surgery, Spedali Civili di Brescia, Brescia, Italy
Michela Buglione Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Francesco Dionisi Radiation Oncology, Regina Elena Institute, IFO, Rome, Italy
Irene Giacomelli Proton Therapy Center, Trento, Italy
Andrea Lancia Department of Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Stefano Maria Magrini Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy
Davide Tomasini Department of Radiation Oncology, Istituto del Radio O. Alberti, University of Brescia and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25121, Brescia, Italy

Collapse

Andersen SN, Bonnen MD, Ludwig MS, Dalwadi SM. Quality Assurance for Stereotactic Body Radiation Therapy for Gynecologic Malignancies. Cureus 2024;16:e53470. [PMID: 38435154 PMCID: PMC10909451 DOI: 10.7759/cureus.53470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2024] [Indexed: 03/05/2024] Open

Starling MTM, Thibodeau S, de Sousa CFPM, Restini FCF, Viani GA, Gouveia AG, Mendez LC, Marta GN, Moraes FY. Optimizing Clinical Implementation of Hypofractionation: Comprehensive Evidence Synthesis and Practical Guidelines for Low- and Middle-Income Settings. Cancers (Basel) 2024;16:539. [PMID: 38339290 PMCID: PMC10854666 DOI: 10.3390/cancers16030539] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 02/12/2024] Open

Ocanto A, Torres L, Montijano M, Rincón D, Fernández C, Sevilla B, Gonsalves D, Teja M, Guijarro M, Glaría L, Hernánz R, Zafra-Martin J, Sanmamed N, Kishan A, Alongi F, Moghanaki D, Nagar H, Couñago F. MR-LINAC, a New Partner in Radiation Oncology: Current Landscape. Cancers (Basel) 2024;16:270. [PMID: 38254760 PMCID: PMC10813892 DOI: 10.3390/cancers16020270] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 01/03/2024] [Accepted: 01/05/2024] [Indexed: 01/24/2024] Open

Affiliation(s)

Abrahams Ocanto Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Lisselott Torres Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Miguel Montijano Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Diego Rincón Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Castalia Fernández Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Beatriz Sevilla Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Daniela Gonsalves Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Macarena Teja Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Marcos Guijarro Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
Luis Glaría Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.)
Raúl Hernánz Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.)
Juan Zafra-Martin Group of Translational Research in Cancer Immunotherapy, Centro de Investigaciones Médico-Sanitarias (CIMES), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), 29010 Málaga, Spain; Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
Noelia Sanmamed Department of Radiation Oncology, Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain;
Amar Kishan Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA;
Filippo Alongi Advanced Radiation Oncology Department, Cancer Care Center, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar, Italy; University of Brescia, 25121 Brescia, Italy
Drew Moghanaki UCLA Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA;
Himanshu Nagar Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA;
Felipe Couñago Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain; (L.T.); (M.M.); (D.R.); (C.F.); (B.S.); (D.G.); (M.T.); (M.G.); (L.G.); (R.H.); (F.C.) Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain GenesisCare, 28043 Madrid, Spain

Collapse

Gill A, Hirst AL, Rowshanfarzad P, Gill S, Bucknell N, Dass J, Sabet M. Stereotactic body radiotherapy for early-stage lung cancer: a systematic review on the choice of photon energy and linac flattened/unflattened beams. Radiat Oncol 2024;19:1. [PMID: 38167095 PMCID: PMC10762943 DOI: 10.1186/s13014-023-02392-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 12/15/2023] [Indexed: 01/05/2024] Open

Anand AK, Kakkar N, Immanuel V, Pannu J, Chaudhoory AR, Malhotra H, Kumar T. Survival and relapse patterns in patients of cranial vs extra-cranial oligometastases treated with stereotactic radiosurgery/stereotactic body radiation therapy and systemic therapy. BJR Open 2024;6:tzae042. [PMID: 39659868 PMCID: PMC11630083 DOI: 10.1093/bjro/tzae042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2024] [Revised: 09/11/2024] [Accepted: 11/20/2024] [Indexed: 12/12/2024] Open

Abualnil AY, Kumar R, George MA, Lalos A, Shah MM, Deek MP, Jabbour SK. Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma. Surg Oncol Clin N Am 2024;33:173-195. [PMID: 37945142 DOI: 10.1016/j.soc.2023.06.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2023]

Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Semin Cancer Biol 2024;98:19-30. [PMID: 38040401 DOI: 10.1016/j.semcancer.2023.11.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 11/16/2023] [Accepted: 11/22/2023] [Indexed: 12/03/2023]

Raj RK, Upadhyay R, Wang SJ, Singer EA, Dason S. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma. Curr Oncol 2023;30:10283-10298. [PMID: 38132383 PMCID: PMC10742565 DOI: 10.3390/curroncol30120749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 11/25/2023] [Accepted: 11/27/2023] [Indexed: 12/23/2023] Open

He L, Peng X, Chen N, Wei Z, Wang J, Liu Y, Xiao J. Automated treatment planning for liver cancer stereotactic body radiotherapy. Clin Transl Oncol 2023;25:3230-3240. [PMID: 37097529 DOI: 10.1007/s12094-023-03196-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2022] [Accepted: 04/07/2023] [Indexed: 04/26/2023]

Hohneck AL, Sadikaj L, Heinemann L, Schroeder M, Riess H, Gerhards A, Burkholder I, Heckel-Reusser S, Gottfried J, Hofheinz RD. Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy: A Retrospective Single-Center Analysis. Cancers (Basel) 2023;15:4929. [PMID: 37894296 PMCID: PMC10605673 DOI: 10.3390/cancers15204929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2023] [Revised: 09/29/2023] [Accepted: 10/08/2023] [Indexed: 10/29/2023] Open

Lee J, Kim JA, An TJ, Lee H, Han EJ, Sa YJ, Kim HR, Park CK, Kim TJ, Lim JU. Optimal timing for local ablative treatment of bone oligometastases in non-small cell lung cancer. J Bone Oncol 2023;42:100496. [PMID: 37589036 PMCID: PMC10425942 DOI: 10.1016/j.jbo.2023.100496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 07/29/2023] [Accepted: 07/31/2023] [Indexed: 08/18/2023] Open

Affiliation(s)

Jayoung Lee Department of Radiation Oncology, The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul 150-713, Republic of Korea
Jung A. Kim Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea Outpatient Department of Respiratory Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Tai Joon An Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Hyochun Lee Department of Radiation Oncology, The Catholic University of Korea, St. Vincent's Hospital, Republic of Korea
Eun Ji Han Division of Nuclear Medicine, Department of Radiology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Young Jo Sa Department of Thoracic and Cardiovascular Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Hyo Rim Kim Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Chan Kwon Park Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Tae-Jung Kim Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea
Jeong Uk Lim Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 150-713, Republic of Korea

Collapse

Id Said B, Mutsaers A, Chen H, Husain ZA, Biswas T, Dagan R, Erler D, Foote M, Louie AV, Redmond K, Ricardi U, Sahgal A, Poon I. Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi-institutional consortium. Head Neck 2023;45:2627-2637. [PMID: 37602655 DOI: 10.1002/hed.27488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 07/28/2023] [Accepted: 08/09/2023] [Indexed: 08/22/2023] Open

Lebow ES, Lobaugh SM, Zhang Z, Dickson MA, Rosenbaum E, D'Angelo SP, Nacev BA, Shepherd AF, Shaverdian N, Wolden S, Wu AJ, Gelblum DY, Simone CB, Gomez DR, Alektiar K, Tap WD, Rimner A. Stereotactic body radiation therapy for sarcoma pulmonary metastases. Radiother Oncol 2023;187:109824. [PMID: 37532104 PMCID: PMC11225867 DOI: 10.1016/j.radonc.2023.109824] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 06/20/2023] [Accepted: 07/20/2023] [Indexed: 08/04/2023]

Affiliation(s)

Emily S Lebow Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Stephanie M Lobaugh Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
Zhigang Zhang Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Mark A Dickson Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Evan Rosenbaum Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Sandra P D'Angelo Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Benjamin A Nacev Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Annemarie F Shepherd Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Narek Shaverdian Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Suzanne Wolden Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Abraham J Wu Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Daphna Y Gelblum Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Charles B Simone Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Daniel R Gomez Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Kaled Alektiar Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
William D Tap Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
Andreas Rimner Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.

Collapse

Bourbonne V, Thureau S, Pradier O, Antoni D, Lucia F. Stereotactic radiotherapy for ultracentral lung tumours. Cancer Radiother 2023;27:659-665. [PMID: 37516640 DOI: 10.1016/j.canrad.2023.06.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Revised: 06/19/2023] [Accepted: 06/22/2023] [Indexed: 07/31/2023]

Ali AM, Greenwood JB, Walls GM, Belshaw L, Agnew CE, McAleese J, Whitten G, Irvine DM, Hounsell AR, McGarry CK. Evaluation of tumour motion and internal/external correlation in lung SABR. Br J Radiol 2023;96:20220461. [PMID: 37393541 PMCID: PMC10461274 DOI: 10.1259/bjr.20220461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 01/05/2023] [Accepted: 05/30/2023] [Indexed: 07/03/2023] Open

Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg 2023;27:1867-1875. [PMID: 37268830 DOI: 10.1007/s11605-023-05712-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 05/13/2023] [Indexed: 06/04/2023]

Affiliation(s)

Yuan-Mao Lin Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Bryan M Fellman Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Ryosuke Taiji Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Iwan Paolucci Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Jessica Albuquerque Marques Silva Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Eugene J Koay Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Rony Avritscher Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Armeen Mahvash Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Emma B Holliday Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Sunyoung S Lee Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Ahmed O Kaseb Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Prajnan Das Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Jean-Nicolas Vauthey Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Bruno C Odisio Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Collapse

de la Pinta C, Sevillano D, Colmenares R, Barrio S, Olavarria A, Palomera A, Romera R, Cobos J, Muriel A, Fernández E, Perna LC, Albillos A, Sancho S. Are liver contour and bone fusion comparable to fiducials for IGRT in liver SBRT? Tech Innov Patient Support Radiat Oncol 2023;27:100215. [PMID: 37744524 PMCID: PMC10511841 DOI: 10.1016/j.tipsro.2023.100215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Revised: 05/28/2023] [Accepted: 06/19/2023] [Indexed: 09/26/2023] Open

Abstract

Introduction

Liver stereotactic body radiotherapy (SBRT) is increasingly being used to treat tumours. The purpose of this study was to compare the differences in patient positioning when using implanted fiducials as surrogates compared to alternative methods based on liver contour or bone registration.

Material and methods

Eighteen patients treated with SBRT who underwent a fiducial placement procedure were included. Fiducial guidance was our gold standard to guide treatment in this study. After recording the displacements, when fusing the planning CT and CBCT performed in the treatment unit using fiducials, liver contour and bone reference, the differences between fiducials and liver contour and bone reference were calculated. Data from 88 CBCT were analyzed. The correlation between the displacements found with fiducials and those performed based on the liver contour and the nearest bone structure as references was determined. The mean, median, variance, range and standard deviation of the displacements with each of the fusion methods were obtained. μ, Ʃ, and σ values and margins were obtained.

Results

Lateral displacements of less than 3 mm with respect to the gold standard in 92% vs. 62.5% of cases using liver contour and bone references, respectively, with 93.2% vs. 65.9% in the AP axis and SI movement in 69.3% vs. 51.1%. The errors μ, σ and Ʃ of the fusions with hepatic contour and bone reference in SI were 0.26 mm, 4 mm and 3 mm, and 0.8 mm, 5 mm and 3 mm respectively.

Conclusion

Our study showed that displacements were smaller with the use of hepatic contour compared to bone reference and comparable to those obtained with the use of fiducials in the lateral, AP and SI motion axes. This would justify that hepatic contouring can be a guide in the treatment of patients in the absence of fiducials.

Collapse

Lalya I, Benchakroun N, Sifat H, El Kacemi H, B Amaoui, El Hfid M, Sahraoui S, El Mazghi SA, Tahri A, Benider A, Acharki A. [Stereotactic radiotherapy in Morocco : Inventory and technological compatibility with the minimum requirements of international recommendations of good practice]. Cancer Radiother 2023;27:676-681. [PMID: 37482465 DOI: 10.1016/j.canrad.2023.06.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 06/07/2023] [Accepted: 06/07/2023] [Indexed: 07/25/2023]

Puckett LL, Titi M, Kujundzic K, Dawes SL, Gore EM, Katsoulakis E, Park JH, Solanki AA, Kapoor R, Kelly M, Palta J, Chetty IJ, Jabbour SK, Liao Z, Movsas B, Thomas CR, Timmerman RD, Werner-Wasik M, Kudner R, Wilson E, Simone CB. Consensus Quality Measures and Dose Constraints for Lung Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel. Pract Radiat Oncol 2023;13:413-428. [PMID: 37075838 DOI: 10.1016/j.prro.2023.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 04/01/2023] [Accepted: 04/03/2023] [Indexed: 04/21/2023]

Affiliation(s)

Lindsay L Puckett Department of Radiation Oncology, Medical College of Wisconsin and Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin.
Mohammad Titi Department of Radiation Oncology, Medical College of Wisconsin and Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin
Ksenija Kujundzic American Society for Radiation Oncology, Arlington, Virginia
Samantha L Dawes American Society for Radiation Oncology, Arlington, Virginia
Elizabeth M Gore Department of Radiation Oncology, Medical College of Wisconsin and Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin
Evangelia Katsoulakis Department of Radiation Oncology, James A. Haley Veterans Affairs Healthcare System, Tampa, Florida
John H Park Department of Radiation Oncology, Kansas City VA Medical Center, Kansas City, Missouri; Department of Radiology, University of Missouri Kansas City School of Medicine, Kansas City, Missouri
Abhishek A Solanki Department of Radiation Oncology, Loyola University and Hines VA Medical Center, Chicago, Illinois
Rishabh Kapoor Department of Radiation Oncology, Virginia Commonwealth University and Hunter Holmes McGuire VA Medical Center, Richmond, Virginia
Maria Kelly Department of Radiation Oncology, VHA National Radiation Oncology Program Office, Richmond, Virginia
Jatinder Palta Department of Radiation Oncology, Virginia Commonwealth University and Hunter Holmes McGuire VA Medical Center, Richmond, Virginia; Department of Radiation Oncology, VHA National Radiation Oncology Program Office, Richmond, Virginia
Indrin J Chetty Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, Michigan
Salma K Jabbour Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Zhongxing Liao Division of Radiation Oncology, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
Benjamin Movsas Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, Michigan
Charles R Thomas Radiation Oncology, Dartmouth Cancer Institute, Hanover, New Hampshire
Robert D Timmerman Department of Radiation Oncology, University of Texas Southwestern Medical School, Dallas, Texas
Maria Werner-Wasik Department of Radiation Oncology, Sydney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, Pennsylvania
Randi Kudner American Society for Radiation Oncology, Arlington, Virginia
Emily Wilson American Society for Radiation Oncology, Arlington, Virginia
Charles B Simone Department of Radiation Oncology, New York Proton Center, New York, New York

Collapse

Sharon S, Daher-Ghanem N, Zaid D, Gough MJ, Kravchenko-Balasha N. The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer. FRONTIERS IN ORAL HEALTH 2023;4:1180869. [PMID: 37496754 PMCID: PMC10366623 DOI: 10.3389/froh.2023.1180869] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 06/27/2023] [Indexed: 07/28/2023] Open

Abstract

Although treatment modalities for head and neck cancer have evolved considerably over the past decades, survival rates have plateaued. The treatment options remained limited to definitive surgery, surgery followed by fractionated radiotherapy with optional chemotherapy, and a definitive combination of fractionated radiotherapy and chemotherapy. Lately, immunotherapy has been introduced as the fourth modality of treatment, mainly administered as a single checkpoint inhibitor for recurrent or metastatic disease. While other regimens and combinations of immunotherapy and targeted therapy are being tested in clinical trials, adapting the appropriate regimens to patients and predicting their outcomes have yet to reach the clinical setting. Radiotherapy is mainly regarded as a means to target cancer cells while minimizing the unwanted peripheral effect. Radiotherapy regimens and fractionation are designed to serve this purpose, while the systemic effect of radiation on the immune response is rarely considered a factor while designing treatment. To bridge this gap, this review will highlight the effect of radiotherapy on the tumor microenvironment locally, and the immune response systemically. We will review the methodology to identify potential targets for therapy in the tumor microenvironment and the scientific basis for combining targeted therapy and radiotherapy. We will describe a current experience in preclinical models to test these combinations and propose how challenges in this realm may be faced. We will review new players in targeted therapy and their utilization to drive immunogenic response against head and neck cancer. We will outline the factors contributing to head and neck cancer heterogeneity and their effect on the response to radiotherapy. We will review in-silico methods to decipher intertumoral and intratumoral heterogeneity and how these algorithms can predict treatment outcomes. We propose that (a) the sequence of surgery, radiotherapy, chemotherapy, and targeted therapy should be designed not only to annul cancer directly, but to prime the immune response. (b) Fractionation of radiotherapy and the extent of the irradiated field should facilitate systemic immunity to develop. (c) New players in targeted therapy should be evaluated in translational studies toward clinical trials. (d) Head and neck cancer treatment should be personalized according to patients and tumor-specific factors.

Collapse

Dahiya DS, Chandan S, Ali H, Pinnam BSM, Gangwani MK, Al Bunni H, Canakis A, Gopakumar H, Vohra I, Bapaye J, Al-Haddad M, Sharma NR. Role of Therapeutic Endoscopic Ultrasound in Management of Pancreatic Cancer: An Endoscopic Oncologist Perspective. Cancers (Basel) 2023;15:3235. [PMID: 37370843 PMCID: PMC10296171 DOI: 10.3390/cancers15123235] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2023] [Revised: 06/08/2023] [Accepted: 06/17/2023] [Indexed: 06/29/2023] Open

La Rosa A, Mittauer KE, Chuong MD, Hall MD, Kutuk T, Bassiri N, McCulloch J, Alvarez D, Herrera R, Gutierrez AN, Tolakanahalli R, Mehta MP, Kotecha R. Accelerated hypofractionated magnetic resonance-guided adaptive radiotherapy for oligoprogressive non-small cell lung cancer. Med Dosim 2023;48:238-244. [PMID: 37330328 DOI: 10.1016/j.meddos.2023.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 04/12/2023] [Accepted: 05/08/2023] [Indexed: 06/19/2023]

Affiliation(s)

Alonso La Rosa Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Kathryn E Mittauer Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
Michael D Chuong Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
Matthew D Hall Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
Tugce Kutuk Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
Nema Bassiri Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
James McCulloch Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
Diane Alvarez Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
Robert Herrera Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
Alonso N Gutierrez Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
Ranjini Tolakanahalli Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
Minesh P Mehta Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
Rupesh Kotecha Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA; Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.

Collapse

Lee J, Nguyen NT, Wright J, Yeung KKD, Sagar S, Kim DH, Ostapiak O, Doerwald-Munoz L, Whelan T. A phase 2 study of stereotactic body radiation therapy for squamous cell carcinoma of the head and neck (SHINE): a single arm clinical trial protocol. BMC Cancer 2023;23:379. [PMID: 37098494 PMCID: PMC10131380 DOI: 10.1186/s12885-023-10807-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Accepted: 04/03/2023] [Indexed: 04/27/2023] Open

Affiliation(s)

Justin Lee Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada. Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada.
Nhu Tram Nguyen Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
James Wright Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
Ka-Kit David Yeung Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
Stephen Sagar Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
Do-Hoon Kim Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
Orest Ostapiak Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
Lilian Doerwald-Munoz Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada
Timothy Whelan Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, CA, L8V 5C2, Canada

Collapse

Carconi C, Cerreti M, Roberto M, Arrivi G, D'Ambrosio G, De Felice F, Di Civita MA, Iafrate F, Lucatelli P, Magliocca FM, Picchetto A, Picone V, Catalano C, Cortesi E, Tombolini V, Mazzuca F, Tomao S. The Management of Oligometastatic Disease in Colorectal Cancer: Present Strategies and Future Perspectives. Crit Rev Oncol Hematol 2023;186:103990. [PMID: 37061075 DOI: 10.1016/j.critrevonc.2023.103990] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 03/29/2023] [Accepted: 04/11/2023] [Indexed: 04/17/2023] Open

Affiliation(s)

Catia Carconi Sant'Andrea University Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy
Micaela Cerreti Sant'Andrea University Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy
Michela Roberto UOC Oncologia A, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, 00161 Rome, Italy.
Giulia Arrivi Oncology Unit, Sant' Andrea University Hospital, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
Giancarlo D'Ambrosio Department of General Surgery, Surgical Specialties and Organ Transplantation, Policlinico Umberto I, "Sapienza" University of Rome, 00161 Rome, Italy
Francesca De Felice Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy
Mattia Alberto Di Civita UOC Oncologia A, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, 00161 Rome, Italy
Franco Iafrate Department of Radiological Sciences, Oncology and Pathology, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Pierleone Lucatelli Vascular and Interventional radiology Unit, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Fabio Massimo Magliocca Vascular and Interventional radiology Unit, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Andrea Picchetto Emergency Department, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Vincenzo Picone UOC Oncologia B, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Carlo Catalano Vascular and Interventional radiology Unit, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Enrico Cortesi UOC Oncologia B, Department of radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy
Vincenzo Tombolini Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy
Federica Mazzuca Oncology Unit, Sant' Andrea University Hospital, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
Silverio Tomao Oncology Unit, Sant' Andrea University Hospital, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy

Collapse

Claridge Mackonis ER, Hardcastle N, Haworth A. A survey of compliance with stereotactic ablative body radiotherapy quality recommendations. J Med Imaging Radiat Oncol 2023. [PMID: 36996443 DOI: 10.1111/1754-9485.13526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 03/05/2023] [Indexed: 04/01/2023]

Li B, Bai F, Yao X, Xu L, Zhao L. Clinical value of styrofoam fixation in intracranial tumor radiotherapy. Front Oncol 2023;13:1131006. [PMID: 37051532 PMCID: PMC10083371 DOI: 10.3389/fonc.2023.1131006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Accepted: 03/17/2023] [Indexed: 03/29/2023] Open

Abstract ObjectiveTo analyze the application value of two postural fixation techniques.(styrofoam combined with head mask and fixed headrest combined with head mask) in intracranial tumor radiotherapy via cone beam computed tomography (CBCT).MethodsThis study included 104 patients with intracranial tumors undergoing radiotherapy. The patients were divided into two groups: Group A (54 cases with styrofoam fixation) and Group B (50 cases with fixed headrest fixation). The positional deviation in 3D space between the two groups was compared using CBCT. The set-up errors were expressed as median (25th percentile, 75th percentile)or M(p25, p75) since the set-up errors in all directions were not normally distributed,The Mann-Whitney U test was performed.ResultsThe age and gender of patients in the two groups were not significantly different. The set-up errors of A in lateral (X), longitudinal (Y), vertical (Z), and yaw(Rtn) axes were 1.0 (0,1) mm, 1.0 (0,1) mm, 1.0 (0,2) mm, and 0.4 (0.1, 0.8) degrees, respectively while the set-up errors of B were 1.0 (0,1) mm, 1.0 (1,2) mm, 1.0 (0,2) mm, and 0.5 (0.15,0.9) degrees, respectively. Moreover, patients in the styrofoam group had significantly smaller set-up errors in the Y-axis than patients in the headrest group (p=0.001). However, set-up errors in the X, Z, and Rtn axes were not significantly different between the two groups. The expansion boundaries of the target area in the X, Y, and Z directions were 1.77 mm, 2.45 mm, and 2.47 mm, respectively. The outer expansion boundaries of the headrest group were 2.03 mm, 3.88 mm, and 2.57 mm in X, Y, and Z directions, respectively. The set-up times of groups A and B were (32.71 ± 5.21) seconds and (46.57 ± 6.68) seconds, respectively (p=0.014). Patients in group A had significantly better comfort satisfaction than patients in group B (p=0.001).ConclusionStyrofoam plus head thermoplastic mask body fixation technique has a higher positional accuracy in intracranial tumor radiotherapy than headrest plus head thermoplastic mask fixation. Besides, styrofoam plus head thermoplastic mask body fixation technique is associated with improved positioning efficiency, and better comfort than headrest plus head thermoplastic mask fixation, and thus can be effectively applied for intracranial tumor radiotherapy positioning. Collapse

Huang YC, Hsieh PY, Wang LY, Tsai TH, Chen YJ, Hsieh CH. Local Liver Irradiation Concurrently Versus Sequentially with Cabozantinib on the Pharmacokinetics and Biodistribution in Rats. Int J Mol Sci 2023;24:ijms24065849. [PMID: 36982920 PMCID: PMC10056485 DOI: 10.3390/ijms24065849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 03/07/2023] [Accepted: 03/16/2023] [Indexed: 03/22/2023] Open

Abstract The aim of this study was to evaluate the radiotherapy (RT)-pharmacokinetics (PK) effect of cabozantinib in concurrent or sequential regimens with external beam radiotherapy (EBRT) or stereotactic body radiation therapy (SBRT). Concurrent and sequential regimens involving RT and cabozantinib were designed. The RT–drug interactions of cabozantinib under RT were confirmed in a free-moving rat model. The drugs were separated on an Agilent ZORBAX SB-phenyl column with a mobile phase consisting of 10 mM potassium dihydrogen phosphate (KH2PO4)–methanol solution (27:73, v/v) for cabozantinib. There were no statistically significant differences in the concentration versus time curve of cabozantinib (AUCcabozantinib) between the control group and the RT2Gy×3 f’x and RT9Gy×3 f’x groups in the concurrent and the sequential regimens. However, compared to those in the control group, the Tmax, T1/2 and MRT decreased by 72.8% (p = 0.04), 49.0% (p = 0.04) and 48.5% (p = 0.04) with RT2Gy×3 f’x in the concurrent regimen, respectively. Additionally, the T1/2 and MRT decreased by 58.8% (p = 0.01) and 57.8% (p = 0.01) in the concurrent RT9Gy×3 f’x group when compared with the control group, respectively. The biodistribution of cabozantinib in the heart increased by 271.4% (p = 0.04) and 120.0% (p = 0.04) with RT2Gy×3 f’x in the concurrent and sequential regimens compared to the concurrent regimen, respectively. Additionally, the biodistribution of cabozantinib in the heart increased by 107.1% (p = 0.01) with the RT9Gy×3 f’x sequential regimen. Compared to the RT9Gy×3 f’x concurrent regimen, the RT9Gy×3 f’x sequential regimen increased the biodistribution of cabozantinib in the heart (81.3%, p = 0.02), liver (110.5%, p = 0.02), lung (125%, p = 0.004) and kidneys (87.5%, p = 0.048). No cabozantinib was detected in the brain in any of the groups. The AUC of cabozantinib is not modulated by irradiation and is not affected by treatment strategies. However, the biodistribution of cabozantinib in the heart is modulated by off-target irradiation and SBRT doses simultaneously. The impact of the biodistribution of cabozantinib with RT9Gy×3 f’x is more significant with the sequential regimen than with the concurrent regimen. Collapse

Harris N, Fraser O, Bauer M, Foroudi F, Bui A, Tebbutt N, Chao M, Lim Joon D. Stereotactic radiotherapy produces a durable response in a peri-rectal GIST. Adv Radiat Oncol 2023;8:101199. [PMID: 37089277 PMCID: PMC10119498 DOI: 10.1016/j.adro.2023.101199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 02/13/2023] [Indexed: 03/06/2023] Open

Goc B, Roch-Zniszczoł A, Larysz D, Zarudzki Ł, Stąpór-Fudzińska M, Rożek A, Woźniak G, Boczarska-Jedynak M, Miszczyk L, Napieralska A. The Effectiveness and Toxicity of Frameless CyberKnife Based Radiosurgery for Parkinson's Disease-Phase II Study. Biomedicines 2023;11:288. [PMID: 36830825 PMCID: PMC9952894 DOI: 10.3390/biomedicines11020288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 01/15/2023] [Accepted: 01/17/2023] [Indexed: 01/21/2023] Open

McGurk R, Naheedy KW, Kosak T, Hobbs A, Mullins BT, Paradis KC, Kearney M, Roback D, Durney J, Adapa K, Chera BS, Marks LB, Moran JM, Mak RH, Mazur LM. Multi-Institutional Stereotactic Body Radiation Therapy Incident Learning: Evaluation of Safety Barriers Using a Human Factors Analysis and Classification System. J Patient Saf 2023;19:e18-e24. [PMID: 35948321 PMCID: PMC9771927 DOI: 10.1097/pts.0000000000001071] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]

Can the use of knowledge-based planning systems improve stereotactic radiotherapy planning? A systematic review. JOURNAL OF RADIOTHERAPY IN PRACTICE 2023. [DOI: 10.1017/s1460396922000437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]

Lapierre A, Badet L, Rouviere O, Crehange G, Berthiller J, Paparel P, Chapet O. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Cancer: 24-Month Results of the RSR1 Phase 1 Dose Escalation Study. Pract Radiat Oncol 2023;13:e73-e79. [PMID: 35842186 DOI: 10.1016/j.prro.2022.06.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 06/13/2022] [Accepted: 06/15/2022] [Indexed: 01/10/2023]

Stereotactic body radiotherapy compared with video‐assisted thoracic surgery after propensity‐score matching in elderly patients with pathologically‐proven early‐stage non‐small cell lung cancer. PRECISION RADIATION ONCOLOGY 2022. [DOI: 10.1002/pro6.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open

Tadimalla S, Wang W, Haworth A. Role of Functional MRI in Liver SBRT: Current Use and Future Directions. Cancers (Basel) 2022;14:cancers14235860. [PMID: 36497342 PMCID: PMC9739660 DOI: 10.3390/cancers14235860] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Revised: 11/23/2022] [Accepted: 11/24/2022] [Indexed: 11/30/2022] Open